The findings suggest a clinically relevant interaction between ayahuasca and SSRIs, as even modest increases in DMT exposure may intensify serotonergic effects in individuals receiving antidepressant therapy. This study provides a mechanistic and quantitative framework for assessing interaction risks between ayahuasca alkaloids and SSRIs, supporting clinical decision-making and harm-reduction...
INTRODUCTION: Ibogaine is a natural hallucinogen with emerging evidence for treating substance use disorders. However, its cardiovascular effects are not fully known, and most clinical data focus on opioid dependence, with limited data for Alcohol Use Disorder (AUD). This study assessed the feasibility, safety, and preliminary effects of ibogaine in patients with AUD. METHOD: In this...
Pain is a protective mechanism that can be classified into acute and chronic types. Ayahuasca is a psychoactive brew rich in dimethyltryptamine or DMT (a 5-HT2A receptor agonist), and harmine (a monoamine-oxidase (MAO) inhibitor) used for religious and therapeutic purposes. Previous preclinical and anecdotal evidence suggests that ayahuasca and its compounds have antinociceptive and...